首页 > 最新文献

Transplant Research and Risk Management最新文献

英文 中文
Hyperosmolar nonketotic hyperglycemic coma induced by methylprednisolone pulse therapy for acute rejection after liver transplantation: A case report and review of the literature 甲泼尼龙脉冲治疗肝移植术后急性排斥反应致高渗性非酮症高血糖昏迷1例报告及文献复习
IF 0.9 Q4 TRANSPLANTATION Pub Date : 2014-12-22 DOI: 10.2147/TRRM.S69516
Jian Zhou, W. Ju, Xiao-Peng Yuan, Xiao-feng Zhu, Dongping Wang, Xiaoshun He
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2015:7 23–26 Transplant Research and Risk Management Dovepress
许可证。许可的完整条款可在http://creativecommons.org/licenses/by-nc/3.0/上获得。允许非商业用途的工作,没有任何进一步的许可,从多芬医学出版社有限公司,只要工作适当署名。超出许可范围的许可由多芬医疗新闻有限公司管理。有关如何请求许可的信息可在http://www.dovepress.com/permissions.php移植研究和风险管理2015:7 23-26移植研究和风险管理Dovepress上找到
{"title":"Hyperosmolar nonketotic hyperglycemic coma induced by methylprednisolone pulse therapy for acute rejection after liver transplantation: A case report and review of the literature","authors":"Jian Zhou, W. Ju, Xiao-Peng Yuan, Xiao-feng Zhu, Dongping Wang, Xiaoshun He","doi":"10.2147/TRRM.S69516","DOIUrl":"https://doi.org/10.2147/TRRM.S69516","url":null,"abstract":"License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2015:7 23–26 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"7 1","pages":"23-26"},"PeriodicalIF":0.9,"publicationDate":"2014-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S69516","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68497476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac allograft immune activation: current perspectives 心脏同种异体移植免疫激活:目前的观点
IF 0.9 Q4 TRANSPLANTATION Pub Date : 2014-12-18 DOI: 10.2147/TRRM.S71055
D. Chang, J. Kobashigawa
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2015:7 13–22 Transplant Research and Risk Management Dovepress
许可证。许可的完整条款可在http://creativecommons.org/licenses/by-nc/3.0/上获得。允许非商业用途的工作,没有任何进一步的许可,从多芬医学出版社有限公司,只要工作适当署名。超出许可范围的许可由多芬医疗新闻有限公司管理。有关如何请求许可的信息可在http://www.dovepress.com/permissions.php移植研究和风险管理2015:7 13-22移植研究和风险管理Dovepress上找到
{"title":"Cardiac allograft immune activation: current perspectives","authors":"D. Chang, J. Kobashigawa","doi":"10.2147/TRRM.S71055","DOIUrl":"https://doi.org/10.2147/TRRM.S71055","url":null,"abstract":"License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2015:7 13–22 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"7 1","pages":"13-22"},"PeriodicalIF":0.9,"publicationDate":"2014-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S71055","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68497557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Organizational determinants in the procurement and transplantation pathway: a review 采购和移植途径中的组织决定因素:综述
IF 0.9 Q4 TRANSPLANTATION Pub Date : 2014-12-17 DOI: 10.2147/TRRM.S67467
M. Triassi, E. Giancotti, A. Nardone, G. Mancini, F. Rubba
s were screened. In the next phase, the full text of all abstracts considered potentially relevant by at least one of the reviewers was evaluated. Inconsistencies in decision-making within this second phase were solved based on consensus between both reviewers. In this phase, for every study we defined whether the organization was considered relevant and what the scenario was. The information was extracted from each study based on bibliographic details (author, journal, year of publication, and language). As many as 1,071 studies were analyzed, and 81 were selected as potentially relevant. Results: We found three prevalent areas of interest focused on organizational elements: global organizational strategies scenario, clinical hospital organization, and citizenship and social scenario. Conclusion: We reached the conclusion that organization has a central role in different scenarios of procurement and transplantation in a continuum from government to hospital (the core of the system) and finally among citizens. A standardized hospital pathway definitely remains the essential step in order to ameliorate either procurement or transplantation.
S被筛选。在下一阶段,对所有被至少一位审稿人认为可能相关的摘要全文进行评估。在第二阶段的决策不一致是基于双方审稿人的共识来解决的。在这个阶段,对于每一个研究,我们定义了组织是否被认为是相关的,以及场景是什么。这些信息是根据文献细节(作者、期刊、出版年份和语言)从每项研究中提取出来的。多达1071项研究被分析,其中81项被选为可能相关的研究。结果:我们发现三个普遍关注组织要素的领域:全球组织战略情景、临床医院组织、公民身份和社会情景。结论:我们得出的结论是,在从政府到医院(系统的核心)以及最终在公民之间的连续体中,组织在不同情况下的采购和移植中发挥着核心作用。标准化的医院途径无疑仍然是改善获取或移植的必要步骤。
{"title":"Organizational determinants in the procurement and transplantation pathway: a review","authors":"M. Triassi, E. Giancotti, A. Nardone, G. Mancini, F. Rubba","doi":"10.2147/TRRM.S67467","DOIUrl":"https://doi.org/10.2147/TRRM.S67467","url":null,"abstract":"s were screened. In the next phase, the full text of all abstracts considered potentially relevant by at least one of the reviewers was evaluated. Inconsistencies in decision-making within this second phase were solved based on consensus between both reviewers. In this phase, for every study we defined whether the organization was considered relevant and what the scenario was. The information was extracted from each study based on bibliographic details (author, journal, year of publication, and language). As many as 1,071 studies were analyzed, and 81 were selected as potentially relevant. Results: We found three prevalent areas of interest focused on organizational elements: global organizational strategies scenario, clinical hospital organization, and citizenship and social scenario. Conclusion: We reached the conclusion that organization has a central role in different scenarios of procurement and transplantation in a continuum from government to hospital (the core of the system) and finally among citizens. A standardized hospital pathway definitely remains the essential step in order to ameliorate either procurement or transplantation.","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"7 1","pages":"1-12"},"PeriodicalIF":0.9,"publicationDate":"2014-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S67467","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68497058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Transplant coronary heart disease: challenges and solutions 移植冠心病:挑战与解决方案
IF 0.9 Q4 TRANSPLANTATION Pub Date : 2014-12-11 DOI: 10.2147/TRRM.S50846
J. Jentzer, G. Hickey, S. Khandhar
© 2014 Jentzer et al. Cardiac allograft vasculopathy (CAV) remains one of the leading causes of death and graft failure after heart transplantation. A variety of causes, including donor heart characteristics, recipient risk factors, and immune-mediated influences, are associated with developing CAV. In this review, we will focus on the pathophysiology of developing CAV and various methods to screen for this condition. The pathogenesis of CAV likely involves repeated injuries to the endothelium from a variety of factors such as cellular-mediated rejection, and alloimmune factors, including antibody-mediated injury, ischemia-reperfusion injury at time of transplant, cytomegalovirus infections, immunosuppression medications, systemic inflammation, and tra­ditional atherosclerosis risk factors. Patients with significant CAV are often asymptomatic, and therefore early detection by routine screening prior to graft dysfunction is crucial. There are a variety of invasive, noninvasive, and blood tests that have been studied as screening methods, and we will discuss the role of each of these in this review article. Although some treatment regimens have been established for CAV, this is an area where further studies and research are necessary.
©2014 Jentzer et al。同种异体心脏移植血管病变(CAV)仍然是心脏移植后死亡和移植物衰竭的主要原因之一。多种原因,包括供体心脏特征、受体危险因素和免疫介导的影响,都与CAV的发生有关。在这篇综述中,我们将重点讨论发生CAV的病理生理以及筛查这种疾病的各种方法。CAV的发病机制可能涉及多种因素对内皮的反复损伤,如细胞介导的排斥反应和同种免疫因素,包括抗体介导的损伤、移植时的缺血再灌注损伤、巨细胞病毒感染、免疫抑制药物、全身性炎症和传统的动脉粥样硬化危险因素。有明显CAV的患者通常是无症状的,因此在移植物功能障碍之前通过常规筛查早期发现是至关重要的。有各种各样的侵入性、非侵入性和血液检查被研究作为筛查方法,我们将在这篇综述文章中讨论每一种方法的作用。虽然已经为CAV建立了一些治疗方案,但这是一个需要进一步研究和研究的领域。
{"title":"Transplant coronary heart disease: challenges and solutions","authors":"J. Jentzer, G. Hickey, S. Khandhar","doi":"10.2147/TRRM.S50846","DOIUrl":"https://doi.org/10.2147/TRRM.S50846","url":null,"abstract":"© 2014 Jentzer et al. Cardiac allograft vasculopathy (CAV) remains one of the leading causes of death and graft failure after heart transplantation. A variety of causes, including donor heart characteristics, recipient risk factors, and immune-mediated influences, are associated with developing CAV. In this review, we will focus on the pathophysiology of developing CAV and various methods to screen for this condition. The pathogenesis of CAV likely involves repeated injuries to the endothelium from a variety of factors such as cellular-mediated rejection, and alloimmune factors, including antibody-mediated injury, ischemia-reperfusion injury at time of transplant, cytomegalovirus infections, immunosuppression medications, systemic inflammation, and tra­ditional atherosclerosis risk factors. Patients with significant CAV are often asymptomatic, and therefore early detection by routine screening prior to graft dysfunction is crucial. There are a variety of invasive, noninvasive, and blood tests that have been studied as screening methods, and we will discuss the role of each of these in this review article. Although some treatment regimens have been established for CAV, this is an area where further studies and research are necessary.","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"6 1","pages":"117-127"},"PeriodicalIF":0.9,"publicationDate":"2014-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S50846","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68496681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Current perspectives on antibody-mediated rejection after lung transplantation 肺移植后抗体介导的排斥反应的研究进展
IF 0.9 Q4 TRANSPLANTATION Pub Date : 2014-10-08 DOI: 10.2147/TRRM.S50799
C. Witt, R. Hachem
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2014:6 109–115 Transplant Research and Risk Management Dovepress
许可证。许可的完整条款可在http://creativecommons.org/licenses/by-nc/3.0/上获得。允许非商业用途的工作,没有任何进一步的许可,从多芬医学出版社有限公司,只要工作适当署名。超出许可范围的许可由多芬医疗新闻有限公司管理。有关如何请求许可的信息可在http://www.dovepress.com/permissions.php移植研究和风险管理2014:6 109-115移植研究和风险管理Dovepress上找到
{"title":"Current perspectives on antibody-mediated rejection after lung transplantation","authors":"C. Witt, R. Hachem","doi":"10.2147/TRRM.S50799","DOIUrl":"https://doi.org/10.2147/TRRM.S50799","url":null,"abstract":"License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2014:6 109–115 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"34 1","pages":"109-115"},"PeriodicalIF":0.9,"publicationDate":"2014-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S50799","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68495786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Transplantation in highly HLA-sensitized patients: challenges and solutions hla高度敏感患者的移植:挑战和解决方案
IF 0.9 Q4 TRANSPLANTATION Pub Date : 2014-09-26 DOI: 10.2147/TRRM.S50793
Irene K Kim, A. Vo, S. Jordan
Despite better understanding of the impact of development of the human leukocyte antigen (HLA) antibody and numerous advancements in immunosuppressive therapy, the abil- ity to successfully transplant highly sensitized patients remains a significant challenge. As the percentage of the waiting list becomes increasingly populated with highly sensitized patients, there is a growing demand for effective strategies to manage these patients. Over the past 20 years, desensitization therapies have been modified and developed, and are mainly utilized at transplant centers that have developed expertise. In addition, recognition that the highly sensitized patient population is disadvantaged on the transplant waiting list has led to recent changes in national kidney allocation policy. Furthermore, creative strategies, such as enroll- ment of sensitized patients into paired kidney exchange programs, have been developed to find compatible matches for these patients. The goal of this article is to address some of the specific challenges related to transplanting the highly sensitized patient at a high-volume transplant center with experience in desensitization and to review established and emerging solutions to help this patient population.
尽管对人类白细胞抗原(HLA)抗体发展的影响有了更好的了解,免疫抑制疗法也取得了许多进展,但成功移植高度敏感患者的能力仍然是一个重大挑战。随着等候名单中高度敏感患者的比例越来越高,对有效管理这些患者的策略的需求日益增长。在过去的20年里,脱敏疗法得到了改进和发展,主要应用于具有专业知识的移植中心。此外,认识到高度敏感的患者群体在移植等待名单上处于不利地位,导致了最近国家肾脏分配政策的变化。此外,创造性的策略,如将敏感患者纳入配对肾脏交换计划,已经开发出适合这些患者的匹配。本文的目的是解决在具有脱敏经验的大容量移植中心移植高度敏感患者的一些具体挑战,并回顾现有的和新兴的解决方案,以帮助这一患者群体。
{"title":"Transplantation in highly HLA-sensitized patients: challenges and solutions","authors":"Irene K Kim, A. Vo, S. Jordan","doi":"10.2147/TRRM.S50793","DOIUrl":"https://doi.org/10.2147/TRRM.S50793","url":null,"abstract":"Despite better understanding of the impact of development of the human leukocyte antigen (HLA) antibody and numerous advancements in immunosuppressive therapy, the abil- ity to successfully transplant highly sensitized patients remains a significant challenge. As the percentage of the waiting list becomes increasingly populated with highly sensitized patients, there is a growing demand for effective strategies to manage these patients. Over the past 20 years, desensitization therapies have been modified and developed, and are mainly utilized at transplant centers that have developed expertise. In addition, recognition that the highly sensitized patient population is disadvantaged on the transplant waiting list has led to recent changes in national kidney allocation policy. Furthermore, creative strategies, such as enroll- ment of sensitized patients into paired kidney exchange programs, have been developed to find compatible matches for these patients. The goal of this article is to address some of the specific challenges related to transplanting the highly sensitized patient at a high-volume transplant center with experience in desensitization and to review established and emerging solutions to help this patient population.","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"6 1","pages":"99-107"},"PeriodicalIF":0.9,"publicationDate":"2014-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S50793","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68495569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Chronic lung allograft dysfunction following lung transplantation: challenges and solutions 肺移植后慢性同种异体肺功能障碍:挑战和解决方案
IF 0.9 Q4 TRANSPLANTATION Pub Date : 2014-09-25 DOI: 10.2147/TRRM.S50896
B. Bemiss, C. Witt
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2014:6 87–97 Transplant Research and Risk Management Dovepress
许可证。许可的完整条款可在http://creativecommons.org/licenses/by-nc/3.0/上获得。允许非商业用途的工作,没有任何进一步的许可,从多芬医学出版社有限公司,只要工作适当署名。超出许可范围的许可由多芬医疗新闻有限公司管理。有关如何请求许可的信息可在http://www.dovepress.com/permissions.php移植研究和风险管理2014:6 87-97移植研究和风险管理Dovepress上找到
{"title":"Chronic lung allograft dysfunction following lung transplantation: challenges and solutions","authors":"B. Bemiss, C. Witt","doi":"10.2147/TRRM.S50896","DOIUrl":"https://doi.org/10.2147/TRRM.S50896","url":null,"abstract":"License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2014:6 87–97 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"2014 1","pages":"87-97"},"PeriodicalIF":0.9,"publicationDate":"2014-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S50896","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68496880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Potential for clinical pancreatic islet xenotransplantation 临床胰岛异种移植的潜力
IF 0.9 Q4 TRANSPLANTATION Pub Date : 2014-09-24 DOI: 10.2147/TRRM.S50850
R. Bottino, S. Nagaraju, V. Satyananda, H. Hara, M. Wijkstrom, M. Trucco, D. Cooper
© 2014 Bottino et al. Diabetes mellitus is increasing worldwide. Type 1 diabetes can be treated successfully by islet allotransplantation, the results of which are steadily improving. However, the number of islets that can be obtained from deceased human donors will never be sufficient to cure more than a very small percentage of patients who might benefit from transplantation. Although there are some differences in glucose metabolism between pigs and humans, the use of pigs could provide an unlimited supply of islets, and the insulin produced would undoubtedly control glucose levels. Transplantation of islets into the portal vein results in islets residing in the liver; however, an early inflammatory response and rejection remain problematic, even when the recipient is receiving immunosuppressive therapy. In the long term, immunosuppressive drugs may exhibit toxicities to patients and specifically harm the islet cells. In contrast, encapsulation techniques provide islets with a physical barrier that prevents antibodies binding to the islet graft while still allowing insulin to be released into the recipient’s circulation; in theory, patients receiving encapsulated grafts might not require exogenous immunosuppressive therapy. Nonhuman primates with encapsulated pig islet transplants have remained insulin-independent for several weeks, but long-term efficacy remains uncertain. Furthermore, techniques are now available to knock out genes from the pig and/or insert human genes, thus rendering the antigenic structure of pigs closer to that of humans, and providing protection from the human immune response. Islet transplantation from genetically engineered pigs has been followed by insulin independence in a small number of nonhuman primates for greater than 1 year. Neonatal islets have some advantages over adult islets in that they are easier to isolate and culture, and have the ability to proliferate during the first few months after transplantation. In 2009, the International Xenotransplantation Association set up a group to encourage and advise on clinical trials of pig islet xenotransplantation; this group’s guidelines are discussed. Clinical trials of encapsulated pig islets are already under way.
©2014 Bottino et al。糖尿病在世界范围内呈上升趋势。同种异体胰岛移植可以成功治疗1型糖尿病,其结果正在稳步改善。然而,从死亡的人类供体中获得的胰岛数量永远不足以治愈可能从移植中受益的一小部分患者。尽管猪和人在葡萄糖代谢方面存在一些差异,但使用猪可以提供无限的胰岛供应,并且产生的胰岛素无疑会控制血糖水平。将胰岛移植到门静脉导致胰岛驻留在肝脏中;然而,早期的炎症反应和排斥反应仍然存在问题,即使受体接受免疫抑制治疗。从长期来看,免疫抑制药物可能对患者产生毒性,并特异性地损害胰岛细胞。相比之下,封装技术为胰岛提供了一个物理屏障,防止抗体与胰岛移植物结合,同时仍允许胰岛素释放到受体的循环中;理论上,接受包封移植物的患者可能不需要外源性免疫抑制治疗。非人类灵长类动物接受封装的猪胰岛移植后,仍可保持胰岛素独立数周,但长期疗效仍不确定。此外,现在有技术可以从猪中敲除基因和/或插入人类基因,从而使猪的抗原结构更接近人类,并提供对人类免疫反应的保护。经过基因工程改造的猪的胰岛移植后,少数非人灵长类动物的胰岛素依赖性已超过1年。新生儿胰岛比成人胰岛有一些优势,因为它们更容易分离和培养,并且在移植后的最初几个月内具有增殖能力。2009年,国际异种移植协会成立了一个小组,鼓励和建议猪胰岛异种移植的临床试验;讨论了该小组的指导方针。猪胰岛封装的临床试验已经在进行中。
{"title":"Potential for clinical pancreatic islet xenotransplantation","authors":"R. Bottino, S. Nagaraju, V. Satyananda, H. Hara, M. Wijkstrom, M. Trucco, D. Cooper","doi":"10.2147/TRRM.S50850","DOIUrl":"https://doi.org/10.2147/TRRM.S50850","url":null,"abstract":"© 2014 Bottino et al. Diabetes mellitus is increasing worldwide. Type 1 diabetes can be treated successfully by islet allotransplantation, the results of which are steadily improving. However, the number of islets that can be obtained from deceased human donors will never be sufficient to cure more than a very small percentage of patients who might benefit from transplantation. Although there are some differences in glucose metabolism between pigs and humans, the use of pigs could provide an unlimited supply of islets, and the insulin produced would undoubtedly control glucose levels. Transplantation of islets into the portal vein results in islets residing in the liver; however, an early inflammatory response and rejection remain problematic, even when the recipient is receiving immunosuppressive therapy. In the long term, immunosuppressive drugs may exhibit toxicities to patients and specifically harm the islet cells. In contrast, encapsulation techniques provide islets with a physical barrier that prevents antibodies binding to the islet graft while still allowing insulin to be released into the recipient’s circulation; in theory, patients receiving encapsulated grafts might not require exogenous immunosuppressive therapy. Nonhuman primates with encapsulated pig islet transplants have remained insulin-independent for several weeks, but long-term efficacy remains uncertain. Furthermore, techniques are now available to knock out genes from the pig and/or insert human genes, thus rendering the antigenic structure of pigs closer to that of humans, and providing protection from the human immune response. Islet transplantation from genetically engineered pigs has been followed by insulin independence in a small number of nonhuman primates for greater than 1 year. Neonatal islets have some advantages over adult islets in that they are easier to isolate and culture, and have the ability to proliferate during the first few months after transplantation. In 2009, the International Xenotransplantation Association set up a group to encourage and advise on clinical trials of pig islet xenotransplantation; this group’s guidelines are discussed. Clinical trials of encapsulated pig islets are already under way.","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"35 2 1","pages":"79-86"},"PeriodicalIF":0.9,"publicationDate":"2014-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S50850","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68496811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Triple antiviral therapy with telaprevir after liver transplantation: a case series 肝移植后用特拉韦三联抗病毒治疗:一个病例系列
IF 0.9 Q4 TRANSPLANTATION Pub Date : 2014-09-09 DOI: 10.2147/TRRM.S65651
J. Knapstein, D. Grimm, M. Wörns, P. Galle, H. Lang, T. Zimmermann
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2014:6 73–78 Transplant Research and Risk Management Dovepress
许可证。许可的完整条款可在http://creativecommons.org/licenses/by-nc/3.0/上获得。允许非商业用途的工作,没有任何进一步的许可,从多芬医学出版社有限公司,只要工作适当署名。超出许可范围的许可由多芬医疗新闻有限公司管理。有关如何请求许可的信息可在http://www.dovepress.com/permissions.php移植研究和风险管理2014:6 73-78移植研究和风险管理Dovepress上找到
{"title":"Triple antiviral therapy with telaprevir after liver transplantation: a case series","authors":"J. Knapstein, D. Grimm, M. Wörns, P. Galle, H. Lang, T. Zimmermann","doi":"10.2147/TRRM.S65651","DOIUrl":"https://doi.org/10.2147/TRRM.S65651","url":null,"abstract":"License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2014:6 73–78 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"6 1","pages":"73-78"},"PeriodicalIF":0.9,"publicationDate":"2014-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S65651","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68496986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Prevention of organ rejection in renal and liver transplantation with extended release tacrolimus 缓释他克莫司预防肾、肝移植器官排斥反应
IF 0.9 Q4 TRANSPLANTATION Pub Date : 2014-09-02 DOI: 10.2147/TRRM.S41381
M. Reschen, C. O'Callaghan
(unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2014:6 55–72 Transplant Research and Risk Management Dovepress
(未移植,v3.0) License。许可的完整条款可在http://creativecommons.org/licenses/by-nc/3.0/上获得。允许非商业用途的工作,没有任何进一步的许可,从多芬医学出版社有限公司,只要工作适当署名。超出许可范围的许可由多芬医疗新闻有限公司管理。有关如何请求许可的信息可在http://www.dovepress.com/permissions.php移植研究和风险管理2014:6 55-72移植研究和风险管理Dovepress上找到
{"title":"Prevention of organ rejection in renal and liver transplantation with extended release tacrolimus","authors":"M. Reschen, C. O'Callaghan","doi":"10.2147/TRRM.S41381","DOIUrl":"https://doi.org/10.2147/TRRM.S41381","url":null,"abstract":"(unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2014:6 55–72 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"6 1","pages":"55-72"},"PeriodicalIF":0.9,"publicationDate":"2014-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S41381","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68495543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Transplant Research and Risk Management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1